Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

GlobeNewswire10-31

Conference call and webcast to begin at 8:30 AM ET AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479818350?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718","is_english":true,"pubTime":"2024-10-31 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479818350","market":"us","top_or_hot":-1,"title":"Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024","media":"GlobeNewswire","content":"<div>\n<p>Conference call and webcast to begin at 8:30 AM ET\nAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s...</p>\n\n<a href=\"https://finance.yahoo.com/news/cassava-sciences-report-third-quarter-123000951.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences to Report Third Quarter 2024 Results on November 7, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cassava-sciences-report-third-quarter-123000951.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Conference call and webcast to begin at 8:30 AM ET\nAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s...</p>\n\n<a href=\"https://finance.yahoo.com/news/cassava-sciences-report-third-quarter-123000951.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/cassava-sciences-report-third-quarter-123000951.html","article_id":"2479818350","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bJl98QTyU0hrC.haxFxmAg--~B/aD03NzM7dz0xMzczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21979d6015cfbdfe43b479a193b60718"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479818350","pubTimestamp":1730377800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Conference call and webcast to begin at 8:30 AM ET. AUSTIN, Texas, Oct. 31, 2024  -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain.Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to recep","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","SAVAW":"Cassava Sciences Warrants","BK4007":"制药","SAVA":"Cassava Sciences Inc","BK4547":"WSB热门概念"},"translate_title":"Cassava Sciences将于2024年11月7日公布2024年第三季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9,"SAVAW":0.9},"content_text":"Conference call and webcast to begin at 8:30 AM ET\nAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.\n\n\n\n \n \n\n\nEvent details:\n\n\n \n \n\n\nDate:\nThursday, November 7th\n\n\nTime:\n8:30 a.m. Eastern Time\n\n\nAudio Webcast:\nhttps://www.CassavaSciences.com/company-presentations\n\n\nOr\n\n\nAudio Webcast:\nhttps://edge.media-server.com/mmc/p/tzb9j3sy\n\n\n \n \n\n\n\nA replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.\nAbout Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.\nSimufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.\nFor more information, please visit: https://www.CassavaSciences.com\nFor More Information Contact:\nInvestorsSandya van der Weidsvonderweid@lifesciadvisors.com\nMediaSitrick And CompanyMike_Sitrick@Sitrick.com\nCompanyEric Schoen, Chief Financial Officer(512) 501-2450ESchoen@CassavaSciences.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479818350"}